---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-010537"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T04:12:15.323522+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mesa Labs expects $271M non-cash impairment charge for FY2024, impacting two divisions

## Summary
- Non-cash impairment of ~$271M for Clinical Genomics and Biopharmaceutical Development divisions in Q4 FY2024.
- Goodwill impairment of ~$123M ($98M Clinical Genomics, $25M Biopharm Dev) and intangible asset impairment of ~$148M ($114M and $34M).
- Driven by restructuring (eliminated 17 positions), loss of Sema4 as customer, macro uncertainty, and higher discount rates.
- Non-cash charge does not affect cash flows from operations; final amounts subject to change upon 10-K filing.
- Management cites new strategies, downward revenue revisions, and elevated interest rates as key factors.

## SEC filing metadata
- accession: 0001437749-24-010537
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.06, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774924010537/0001437749-24-010537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774924010537/mlab20240401_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-010537
- JSON: https://secwatch.observer/filing/0001437749-24-010537.json
- Plain text: https://secwatch.observer/filing/0001437749-24-010537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.